cyc 202 has been researched along with at 7519 in 8 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (at 7519) | Trials (at 7519) | Recent Studies (post-2010) (at 7519) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 27 | 0 | 24 |
| Protein | Taxonomy | cyc 202 (IC50) | at 7519 (IC50) |
|---|---|---|---|
| Cyclin-T1 | Homo sapiens (human) | 0.0093 | |
| Cyclin-dependent kinase 14 | Homo sapiens (human) | 0.0198 | |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | 0.1729 | |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.0939 | |
| G2/mitotic-specific cyclin-B1 | Homo sapiens (human) | 0.1682 | |
| Cyclin-A2 | Homo sapiens (human) | 0.063 | |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.1168 | |
| G1/S-specific cyclin-E1 | Homo sapiens (human) | 0.36 | |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | 0.0586 | |
| G1/S-specific cyclin-D3 | Homo sapiens (human) | 0.153 | |
| Glycogen synthase kinase-3 beta | Homo sapiens (human) | 0.2 | |
| Cyclin-dependent kinase 7 | Homo sapiens (human) | 2.4 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 0.0094 | |
| Cyclin-H | Homo sapiens (human) | 2.4 | |
| CDK-activating kinase assembly factor MAT1 | Homo sapiens (human) | 2.4 | |
| Cyclin-A1 | Homo sapiens (human) | 0.047 | |
| Cyclin-dependent kinase 3 | Homo sapiens (human) | 0.36 | |
| Cyclin-dependent kinase 6 | Homo sapiens (human) | 0.1775 | |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | 0.1393 | |
| Cyclin-dependent kinase 5 activator 1 | Homo sapiens (human) | 0.1813 | |
| Cyclin-Y | Homo sapiens (human) | 0.0198 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Berdini, V; Boulstridge, JA; Carr, MG; Cross, DM; Davis, DJ; Devine, LA; Early, TR; Feltell, RE; Lewis, EJ; McMenamin, RL; Navarro, EF; O'Brien, MA; O'Reilly, M; Reule, M; Saxty, G; Seavers, LC; Smith, DM; Squires, MS; Trewartha, G; Walker, MT; Woodhead, AJ; Woolford, AJ; Wyatt, PG | 1 |
| Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
| Joshi, G; Kalra, S; Kumar, R; Munshi, A | 1 |
| Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP | 1 |
| Kizhake, S; Natarajan, A; Rana, S; Sonawane, YA; Taylor, MA; Zahid, M | 1 |
| Bian, J; Li, Z; Qin, Z; Tian, Y; Wang, J; Wu, T; Xu, C | 1 |
| Chen, K; Jiang, H; Li, J; Li, Y; Lin, T; Liu, L; Luo, C; Xu, P; Zhou, B | 1 |
| Li, J; Liang, C; Liu, C; Qiang, T; Ren, X; Shi, Z; Tian, L; Xing, Y | 1 |
3 review(s) available for cyc 202 and at 7519
| Article | Year |
|---|---|
Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors.
Topics: Amino Acid Sequence; Animals; Computer-Aided Design; Crystallography, X-Ray; Cyclin-Dependent Kinases; Drug Design; Humans; Models, Molecular; Neoplasms; Protein Conformation; Protein Kinase Inhibitors; Sequence Alignment | 2017 |
Recent Developments in the Biology and Medicinal Chemistry of CDK9 Inhibitors: An Update.
Topics: Animals; Antineoplastic Agents; Chemistry, Pharmaceutical; Cyclin-Dependent Kinase 9; Drug Development; Humans; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Protein Structure, Secondary | 2020 |
From Structure Modification to Drug Launch: A Systematic Review of the Ongoing Development of Cyclin-Dependent Kinase Inhibitors for Multiple Cancer Therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinases; Female; Humans; Pharmaceutical Preparations; Protein Kinase Inhibitors | 2022 |
5 other study(ies) available for cyc 202 and at 7519
| Article | Year |
|---|---|
Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Crystallography, X-Ray; Cyclin-Dependent Kinase 2; Drug Design; Enzyme Inhibitors; Humans; Mice; Piperidines; Pyrazoles; Structure-Activity Relationship | 2008 |
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
The target landscape of clinical kinase drugs.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays | 2017 |
Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy.
Topics: Amination; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 5; Humans; Molecular Docking Simulation; Pancreatic Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Structure-Activity Relationship | 2018 |
Design, synthesis, and biological evaluation of 4-benzoylamino-1H-pyrazole-3-carboxamide derivatives as potent CDK2 inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 2; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Docking Simulation; Molecular Structure; Protein Binding; Protein Kinase Inhibitors; Pyrazoles; Signal Transduction; Structure-Activity Relationship | 2021 |